biostudies-literatureJohnson NAMedical Research CouncilNCI NIH HHS2273-9https://www.ebi.ac.uk/biostudies/studies/S-EPMC2745846biostudies-literatureUnknown114(11)BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2(+)/MYC(+)) were identified in 54 samples by karyotype and/or fluorescence in situ hybridization with the aim of correlating clinical and cytogenetic characteristics to overall survival. BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1). Despite the presence of a t(14;18), 5 cases were BCL2 protein-negative. Nonimmunoglobulin gene/MYC (non-IG/MYC) translocations occurred in 24 of 54 cases (44%) and were highly associated with DLBCL morphology (P < .001). Over a median follow-up of 5.3 years, 6 patients remaiBloodLymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.PMC2745846MC_U132670597UO1-CA84967-1U01 CA084967Ben-Neriah SSiebert RConnors JMSavage KJWoods RKlasa RLudkovski OKuruvilla JSteidl CJohnson NAGascoyne RDDyer MJHorsman DEfalseLymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2(+)/MYC(+)) were identified in 54 samples by karyotype and/or fluorescence in situ hybridization with the aim of correlating clinical and cytogenetic characteristics to overall survival. BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1). Despite the presence of a t(14;18), 5 cases were BCL2 protein-negative. Nonimmunoglobulin gene/MYC (non-IG/MYC) translocations occurred in 24 of 54 cases (44%) and were highly associated with DLBCL morphology (P < .001). Over a median follow-up of 5.3 years, 6 patients remai2009-01-01T00:00:00Z2009 Sep2026-03-16T16:54:33.609Z2025-09-01T03:06:37.554ZS-EPMC27458461959718410.1182/blood-2009-03-212191